Biopharma Daily Stock Updates - 02/05/21

$XBI $166.78 +2% 📈

PIPELINE:

$TGTX +12% UKINIQ FDA approval for adult patients with relapsed or refractory marginal zone lymphoma after at least one prior anti-CD20 based regimen. source

$SPRO +5% Phase 2a put on clinical hold following animal toxicology data. source

$AZN -1% Phase 3 trial did not meet primary/secondary endpoints. source

FINANCIAL:

$ORTX +19% $150 Million Strategic Financing. source

$RYTM +4% Prices offering at $30/share. source